DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Aqueous Humor Dynamics and Brimonidine

Information source: University of Nebraska
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Intraocular Pressure

Intervention: Brimonidine (Drug); Artificial tears (Drug)

Phase: N/A

Status: Not yet recruiting

Sponsored by: University of Nebraska

Official(s) and/or principal investigator(s):
Carol B Toris, PhD, Principal Investigator, Affiliation: Research Instructor

Overall contact:
Susan L Galata, BA, Phone: 402-559-5706, Email: slgalata@unmc.edu


Investigate nocturnal effects on aqueous humor dynamics of a clinically used eye pressure

- lowering drug, brimonidine, when given for six weeks.

Clinical Details

Official title: Circadian Rhythms of Aqueous Humor Dynamics in Subjects With Ocular Hypertension Using Brimonidine

Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Aqueous Humor Dynamics

Detailed description: This single-center, investigator-masked, crossover study is designed to investigate the circadian rhythms of aqueous humor dynamics in human subjects with ocular hypertension (OHT) before and after intervention with a commonly used ocular hypotensive medication, brimonidine. Thirty volunteers with ocular hypertension (intraocular pressure greater than 20mmHg) will be enrolled. The subjects will undergo a baseline phase and medication phase using brimonidine. At both phases, they will attend a daytime and a nighttime study visit in which fluorophotometry will be used to calculate aqueous flow (production), trabecular outflow facility, and uveoscleral outflow. At the completion of the study, subjects will return to their previous ophthalmic clinic.


Minimum age: 19 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Subjects must be 19 years of age or older

- Subjects must exhibit a history of untreated IOPs between 21 and 35 mmHg (inclusive)

Exclusion Criteria:

- Age less than nineteen years old

- Women who are pregnant, lactating or of childbearing potential who are not using

birth control measures.

- Aphakia or pseudophakia

- Best corrected visual acuity worse than 20/60 in either eye

- Chronic or recurrent severe ocular inflammatory disease

- Ocular infection or inflammation within (3) months of screening visit.

- History of clinically significant or progressive retinal disease such as retinal

degeneration, diabetic retinopathy or retinal detachment.

- Any abnormality preventing reliable tonometry of either eye.

- Previous exposure to: beta-adrenergic antagonists, topical prostaglandin analogues

within six (6) weeks of the baseline visit; α-adrenergic agonists within two (2) weeks of the baseline visit; and cholinergic agonists and carbonic anhydrase inhibitors within five (5) days of the treatment initiation visit.

- History of any severe ocular pathology (including severe dry eye) that would prelude

the administration of a topical beta blocker, carbonic anhydrase inhibitor, or a topical prostaglandin.

- Any eye with a cup-to-disc ratio greater than 0. 8.

- History of intraocular surgery

- History of ocular laser surgery

- History of severe or serious hypersensitivity to brimonidine or its vehicle.

- History of severe, unstable, or uncontrolled cardiovascular, hepatic or renal


- History of bronchial asthma or chronic obstructive pulmonary disease (COPD).

- Less than one month (prior to baseline) stable dosing regimen of any non-glaucoma

medication that would affect IOP.

- Gonioscopy angle < 2.

- Inability to be dosed with treatment medication

- Inability to discontinue contact lens wear.

- Therapy with any investigational agent within 30 days of screening.

- Use of any additional topical or systemic adjunctive ocular hypotensive medications

during the study.

- History of open angle glaucoma (either primary open angle glaucoma or other cause of

open angle glaucoma) or narrow angle glaucoma.

Locations and Contacts

Susan L Galata, BA, Phone: 402-559-5706, Email: slgalata@unmc.edu

University of Nebraska Medical Center, Omaha, Nebraska 68198-5540, United States
Additional Information

Starting date: July 2010
Last updated: June 14, 2010

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017